Results 111 to 120 of about 1,098,931 (194)

Immune thrombocytopenia: Evolving mechanistic understanding and clinical development of new therapies

Tzu Chi Medical Journal
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia resulting from increased platelet destruction, impaired platelet production, or both.
Sheng-Chuan Huang, Chih-Lung Shen, Yi-Feng Wu   +2 more
doaj   +1 more source

Treatment patterns and outcomes among patients treated with second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia

Next-generation Bruton tyrosine kinase inhibitors (BTKis) are standards of care for chronic lymphocytic leukemia (CLL). This study evaluated demographic and clinical characteristics, real-world treatment patterns, and outcomes among patients treated with
Qianhong Fu, Kanika Chandra, Vivek A. Rudrapatna, Aryan Ayati, Marjan Massoudi, Madhav Seshadri, Xiaoliang Wang, Gregory A. Maglinte   +7 more
core   +1 more source

Bruton tyrosine kinase inhibitors for multiple sclerosis. [PDF]

Nat Rev Neurol, 2023
Krämer J, Bar-Or A, Turner TJ, Wiendl H.   +3 more
europepmc   +1 more source

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance

, 2017
Nazanin Aghel,1 Diego Hernan Delgado,1 Jeffrey Howard Lipton2 1Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network,University of Toronto, 2Department of Medical Oncology and Hematology, Princess Margaret
Aghel N, Delgado DH, Lipton JH
core  

Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro

, 2018
Jennifer Bourn,1,2 Maria Cekanova1,2 1Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, USA; 2UT-ORNL Graduate School of Genome Science and Technology, The University of Tennessee ...
Bourn J, Cekanova M
core  

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. [PDF]

Am J Hematol, 2023
Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP.   +4 more
europepmc   +1 more source

Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. [PDF]

Clin Lymphoma Myeloma Leuk, 2023
Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA.   +8 more
europepmc   +1 more source

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis. [PDF]

Cureus
Singh M, Podder D, Jacoby AP, Saha S, Chatterji S, Ghosh S, Chattopadhyay D, Kumar J, Nag A, Javed R, Rath A, Chakraborty S, Demde R, Ghosh P, Parihar M, Zameer L, Goel G, Bhattacharya S, Majumder P, Chandy M, Nair R.   +20 more
europepmc   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source